Entrada Therapeutics
One Design Center Place Suite 17- 500
Boston
Massachusetts
02210
United States
Tel: +1-857-520-9158
Website: https://www.entradatx.com/
About Entrada Therapeutics
Entrada Therapeutics is a biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines, Endosomal Escape Vehicle (EEV™) therapeutics, to engage intracellular targets that have long been considered inaccessible and undruggable. The Company’s EEV therapeutics are designed to enable the efficient intracellular delivery of a wide range of therapeutics into a variety of organs and tissues with an improved therapeutic index. Through its proprietary, highly versatile and modular EEV platform, Entrada is building a robust development portfolio of oligonucleotide-, antibody- and enzyme-based programs for the potential treatment of neuromuscular diseases, immunology, oncology and diseases of the central nervous system. The Company’s lead oligonucleotide programs include ENTR-601-44 targeting Duchenne muscular dystrophy (DMD) and ENTR-701 targeting myotonic dystrophy type 1 (DM1).
Stock Symbol: TRDA
Stock Exchange: NASDAQ
CONNECT
“Most targets for drug development are actually intracellular,” says Dipal Doshi, President and CEO of Entrada Therapeutics. “Think about how many drugs can be made that can help patients if we can figure out a way to effectively get inside the cell…that’s why Entrada’s important.”
52 articles about Entrada Therapeutics
-
Entrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
3/13/2024
Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible.
-
Entrada Therapeutics to Present at Upcoming Investor Conferences - February 7, 2024
2/7/2024
Entrada Therapeutics, Inc. today announced it will participate in the following two investor conferences: Oppenheimer 34th Annual Healthcare Life Sciences Conference.
-
Entrada Therapeutics Promotes Nathan J. Dowden to President
1/3/2024
Entrada Therapeutics, Inc. announced that Nathan J. Dowden, current Chief Operating Officer of Entrada Therapeutics, has been promoted to President and Chief Operating Officer, effective as of January 1, 2024.
-
Entrada Therapeutics Announces Updates on ENTR-601-44 in Duchenne Muscular Dystrophy
11/22/2023
Entrada Therapeutics, Inc. today announced the completion of dosing for the first and second cohorts of its Phase 1 clinical trial, ENTR-601-44-101.
-
Entrada Therapeutics Reports Third Quarter 2023 Financial Results
11/7/2023
Entrada Therapeutics, Inc. reported financial results for the third quarter ending September 30, 2023, and highlighted recent business updates.
-
Entrada Therapeutics to Present at Upcoming Investor Conferences
10/12/2023
Entrada Therapeutics, Inc. today announced it will participate in the following two investor conferences.
-
Entrada Therapeutics Announces First Participant Dosed in its Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular Dystrophy
9/21/2023
Entrada Therapeutics, Inc. announced that the first participant has been dosed in its Phase 1 clinical trial evaluating ENTR-601-44 for the potential treatment of individuals with Duchenne muscular dystrophy who are exon 44 skipping amenable.
-
Entrada Therapeutics Awards Funding to Non-Profit Organizations Advancing Diversity, Equity, Inclusion and Accessibility within the Duchenne Muscular Dystrophy Community
9/14/2023
Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEVÔ)
-
Entrada Therapeutics to Present at Upcoming September 2023 Investor Conferences
8/29/2023
Entrada Therapeutics, Inc., a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle -therapeutics as a new class of medicines, announced the Company will participate in two investor conferences in September.
-
Entrada Therapeutics Appoints Gina Chapman to its Board of Directors
8/10/2023
Entrada Therapeutics, Inc., a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle -therapeutics as a new class of medicines, announced the appointment of Gina Chapman to its Board of Directors, effective September 1, 2023.
-
Entrada Therapeutics Reports Second Quarter 2023 Financial Results
8/8/2023
Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™)-therapeutics as a new class of medicines, today reported financial results for the second quarter ending June 30, 2023, and highlighted recent business updates.
-
Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular Dystrophy
8/1/2023
Entrada Therapeutics, Inc. today announced that it has received authorization from the United Kingdom Medicines and Healthcare Products Regulatory Agency (MHRA) and Research Ethics Committee (REC) for its CTIMP (Clinical Trial of an Investigational Medicinal Product) for a Phase 1 clinical trial in healthy volunteers for ENTR-601-44.
-
Entrada Therapeutics to Present at Goldman Sachs 44th Annual Global Healthcare Conference
6/6/2023
Entrada Therapeutics, Inc. today announced that Dipal Doshi, President and Chief Executive Officer, will participate in a fireside chat at the Goldman Sachs 44th Annual Global Healthcare Conference in Dana Point, CA.
-
Entrada Therapeutics Reports First Quarter 2023 Financial Results
5/10/2023
Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™)-therapeutics as a new class of medicines, today reported financial results for the first quarter ending March 31, 2023, and highlighted recent business updates.
-
Entrada Therapeutics Appoints Dr. Bernhardt Zeiher to its Board of Directors
4/4/2023
Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™)-therapeutics as a new class of medicines, today announced the appointment of Dr. Bernhardt “Bernie” Zeiher to its Board of Directors, effective immediately.
-
Entrada Therapeutics to Participate in Guggenheim Genomic Medicines and Rare Disease Conference
3/29/2023
Entrada Therapeutics, Inc. today announced that Dipal Doshi, President and Chief Executive Officer, will participate in a virtual fireside chat during the Guggenheim Genomic Medicines and Rare Disease Conference on Tuesday, April 4, 2023 at 9:00 a.m. Eastern Time.
-
Entrada Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
3/6/2023
Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™) therapeutics as a new class of medicines, today reported financial results for the fourth quarter and full year ending December 31, 2022 and highlighted recent business updates.
-
Entrada Therapeutics to Participate in Cowen 43rd Annual Health Care Conference
2/27/2023
Entrada Therapeutics, Inc. today announced that Dipal Doshi, President and Chief Executive Officer, will participate on the Neuromuscular and Bone Corporate Panel at the Cowen 43rd Annual Health Care Conference.
-
Entrada Therapeutics Closes Agreement with Vertex to Discover and Develop Endosomal Escape Vehicle-Therapeutics for Myotonic Dystrophy Type 1 (DM1)
2/9/2023
Entrada Therapeutics, Inc. today announced the expiration of the waiting period under the Hart-Scott-Rodino (HSR) Antitrust Improvements Act of 1976 and closing of the Company’s previously announced strategic collaboration and license agreement with Vertex.
-
Entrada Therapeutics Announces Clinical Candidate, ENTR-601-45, for the Potential Treatment of People Living with Duchenne Muscular Dystrophy who are Exon 45 Skipping Amenable
1/9/2023
Entrada Therapeutics, Inc., a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle -therapeutics as a new class of medicines, announced the selection of a second clinical candidate within its Duchenne franchise, ENTR-601-45, for the potential treatment of people living with Duchenne who are exon 45 skipping amenable.